St. Louis School of Medicine: Newly Approved Drug Effective Against Lung Cancer Caused by Genetic Mutation
June 05, 2021
June 05, 2021
ST. LOUIS, Missouri, June 5 (TNSJou) -- The Washington University St. Louis School of Medicine issued the following news release:
Medical oncologist and senior author of a new lung cancer study, Ramaswamy Govindan, MD, of Washington University School of Medicine in St. Louis, talks about the newly FDA-approved drug sotorasib. The new study shows that sotorasib benefits some patients who have non-small-cell lung cancer that has a specific mutation in the KRAS gene. Ongoing clinical t . . .
Medical oncologist and senior author of a new lung cancer study, Ramaswamy Govindan, MD, of Washington University School of Medicine in St. Louis, talks about the newly FDA-approved drug sotorasib. The new study shows that sotorasib benefits some patients who have non-small-cell lung cancer that has a specific mutation in the KRAS gene. Ongoing clinical t . . .